Access Bio, Inc. (950130.KQ)
- Previous Close
5,050.00 - Open
5,030.00 - Bid 5,120.00 x --
- Ask 5,130.00 x --
- Day's Range
4,995.00 - 5,160.00 - 52 Week Range
4,380.00 - 11,100.00 - Volume
78,637 - Avg. Volume
89,153 - Market Cap (intraday)
180.09B - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 28, 2022
- 1y Target Est
--
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.
accessbio.net--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 950130.KQ
View MorePerformance Overview: 950130.KQ
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 950130.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 950130.KQ
View MoreValuation Measures
Market Cap
177.63B
Enterprise Value
-211.22B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.58
Price/Book (mrq)
0.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.31%
Return on Assets (ttm)
-1.10%
Return on Equity (ttm)
-0.17%
Revenue (ttm)
112.46B
Net Income Avi to Common (ttm)
-347.58M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
454.85B
Total Debt/Equity (mrq)
10.12%
Levered Free Cash Flow (ttm)
23.76B